Sanofi: positive results of Sarclisa against multiple myeloma – 06/04/2024 at 09:41


(AOF) – Sanofi announces that Sarclisa (isatuximab) is capable of significantly improving the progression-free survival of patients with newly diagnosed multiple myeloma who are not eligible for transplantation. These data from the Imroz phase III study. “The results of the Imroz study illustrate the promising profile of Sarclisa and show that it could become an essential element of first-line treatment and improve the long-term results of this incurable disease,” announces Dr. Thierry Facon, principal investigator. of the study.

AOF – LEARN MORE

Learn more about the Pharmacy sector

Oncology, priority of pharmaceutical giants

Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.



Source link -86